Patient Characteristics for Second-Line HCC Therapy Comparison Study

81 patient records from a retrospective study comparing second-line therapies for unresectable hepatocellular carcinoma. The dataset, authored by Chinatsu Nishioka and last updated in May 2026, contains real-world data from patients who received either durvalumab plus tremelimumab (n=14) or lenvatinib (n=67) after first-line atezolizumab plus bevacizumab.

Use Cases

• Compare progression-free survival (PFS) and overall survival (OS) between two second-line therapy regimens.
• Analyze the frequency and severity of adverse events (AEs) associated with different treatments.
• Assess changes in liver function using the albumin–bilirubin (ALBI) score over time.
• Investigate the relationship between neutrophil-to-lymphocyte ratio and patient survival outcomes.

Strengths

• Includes data for 81 patients from a real-world observational cohort.
• Compares two distinct second-line therapy groups with specific patient counts (14 vs. 67).
• Contains key clinical metrics: objective response rate, disease control rate, PFS, OS, and ALBI scores.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 13.5 KB, indicating limited scope.

Provenance

Source

figshare, authored by Chinatsu Nishioka.

Collection Method

Retrospective analysis of real-world data from a prospectively registered observational cohort.

Time Range

null

Freshness

Last updated 2026-05-07 18:00:11; freshness should be verified.

Geography

null